Galectin-3 is known to reflect myocardial fibrosis and remodeling—key pathophysiological processes in DBCM—and has shown prognostic associations with both systolic/diastolic dysfunction and cardiovascular outcomes among individuals with T2DM [38,39]. Here, LGALS3 is linked to type 2 diabetes mellitus.